ALNFL Stock Overview
NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
NFL Biosciences SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €2.82 |
52 Week High | €3.32 |
52 Week Low | €0.94 |
Beta | 0 |
1 Month Change | 38.57% |
3 Month Change | 98.59% |
1 Year Change | 3.68% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -24.19% |
Recent News & Updates
Recent updates
Shareholder Returns
ALNFL | FR Biotechs | FR Market | |
---|---|---|---|
7D | -7.8% | -0.2% | -0.4% |
1Y | 3.7% | -1.8% | 10.6% |
Return vs Industry: ALNFL exceeded the French Biotechs industry which returned -2.2% over the past year.
Return vs Market: ALNFL underperformed the French Market which returned 10.1% over the past year.
Price Volatility
ALNFL volatility | |
---|---|
ALNFL Average Weekly Movement | 19.4% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.3% |
10% most volatile stocks in FR Market | 10.0% |
10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALNFL's share price has been volatile over the past 3 months.
Volatility Over Time: ALNFL's weekly volatility has increased from 14% to 19% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | n/a | Ignacio Faus | https://www.nflbiosciences.com |
NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. The company’s natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. NFL Biosciences SA was incorporated in 2006 and is based in Castelnau-le-Lez, France.
NFL Biosciences SA Fundamentals Summary
ALNFL fundamental statistics | |
---|---|
Market cap | €22.86m |
Earnings (TTM) | €0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs ALNFL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALNFL income statement (TTM) | |
---|---|
Revenue | €0 |
Cost of Revenue | €0 |
Gross Profit | €0 |
Other Expenses | €0 |
Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
Mar 29, 2024
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did ALNFL perform over the long term?
See historical performance and comparison